# Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

> **NCT00560313** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 54 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** Men ACWY CRM
- **BIOLOGICAL:** 4CMenB

## Key facts

- **NCT ID:** NCT00560313
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560313, "Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00560313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*